My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Atezolizumab Biosimilar, PD-L1 Monoclonal Antibody

Atezolizumab Biosimilar, PD-L1 Monoclonal Antibody

Programmed death-ligand 1, PD-L1, cluster of differentiation 274, CD274, B7 homolog 1, B7-H1

Catalog No. Product Name Size List Price (US$) Quantity
C024P Atezolizumab Biosimilar, Human PD-L1 Monoclonal Antibody 1 mg 175.00
C024P Atezolizumab Biosimilar, Human PD-L1 Monoclonal Antibody 5 mg 600.00
C024P Atezolizumab Biosimilar, Human PD-L1 Monoclonal Antibody 20 mg 1200.00
C024P.05 Atezolizumab Biosimilar, Endotoxin 0.05 EU/mg 5 mg 900.00
C024P.05 Atezolizumab Biosimilar, Endotoxin 0.05 EU/mg 20 mg 1800.00
C024P.h1 Atezolizumab Biosimilar, Human IgG1 1 mg 650.00
C024P.4S Atezolizumab Biosimilar, Human IgG4 S228P Mutant 1 mg 650.00
C024P.4S.05 Atezolizumab Biosimilar, Human IgG4 S228P Mutant, Endotoxin 0.05 EU/mg 1 mg 950.00
C024P.hLA Atezolizumab Biosimilar, Human IgG1 L234A L235A P329G (LALAPG) Fc Silent Mutant 1 mg 650.00
C024P.hLA.05 Atezolizumab Biosimilar, Human IgG1 L234A L235A P329G (LALAPG) Fc Silent Mutant, Endotoxin 0.05 EU/mg 1 mg 950.00
C024P.m1 Atezolizumab Biosimilar, Mouse IgG1 1 mg 650.00
C024P.m1DA Atezolizumab Biosimilar, Mouse IgG1 D265A Mutant 1 mg 650.00
C024P.m2a Atezolizumab Biosimilar, Mouse IgG2a 1 mg 650.00
C024P.m2aLA Atezolizumab Biosimilar, Mouse IgG2a L234A L235A P329G (LALAPG) Fc Silent Mutant 1 mg 650.00
Description

C024P: Atezolizumab Biosimilar, PD-L1 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody atezolizumab biosimilar was produced in the atezolizumab biosimilar CHO stable cell line.
Specificity/Sensitivity: The in vivo grade atezolizumab biosimilar specifically binds to the human PDL1 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by atezolizumab.
Form of Antibody: 0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade atezolizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is Atezolizumab biosimilar research grade? Atezolizumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Atezolizumab biosimilar uses the same protein sequences as the therapeutic antibody atezolizumab. Atezolizumab lacks the N-glycosylation site in its Fc region by changing an aspartic acid into alanine at amino acid position 298 (amino acid position 297 according to EU nomenclature, N297A) in the heavy chain leading to minimized binding to FcγRs.

PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Atezolizumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.

Syd Labs also provides the following research grade anti-PD-L1 / PD-1 antibody biosimilar proteins:
Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Spartalizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody

PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. Syd Labs also provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody

Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies:
In vivo grade recombinant anti-mouse PD1 monoclonal antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD-L1 monoclonal antibodies (Clone 10F.9G2.1)

Related Links

See our Privacy Policy